News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio’s Scaled m-ceNK Clinical Program https://ir.immunitybio.com/news-releases/news-release-details/memory-cytokine-enhanced-natural-killer-cells-show-promising?field_nir_news_date_value[min]=

This Post-Effective Amendment No. 1 contains: a base prospectus which covers the offering, issuance and sale by us of up to $330,795,982 in the aggregate of the securities identified above from time to time in one or more offerings; and  a sale agreement prospectus supplement covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $330,795,982 of our common stock that may be issued and sold under a sale agreement with Jefferies LLC, or Jefferies. https://quantisnow.com/insight/2501489

The Worldwide Merkel Cell Carcinoma Disease Treatment Industry is Expected to Reach $3.7 Billion by 2026 https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/worldwide-merkel-cell-carcinoma-disease-120800044.html

Billionaire Soon-Shiong's firm lost 80% of its value in a year, but he has high hopes for SA plant https://www.google.com/amp/s/www.news24.com/amp/fin24/companies/billionaire-soon-shiongs-firm-lost-80-of-its-value-in-a-year-but-he-has-high-hopes-for-sa-plant-20220222

'The idea that there's not enough human capital in South Africa is outrageous': Dr. Patrick Soon-Shiong https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/the-idea-that-theres-not-enough-human-capital-in-south-africa-is-outrageous-dr-patrick-soon-shiong-143221817.html

Neues Yahoo Finance Video mit Patrick Soon Shiong https://finance.yahoo.com/video/yahoo-finance-presents-dr-patrick-120000550.html

ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-acquisition-athenexs-interest-dunkirk-new?field_nir_news_date_value[min]=

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical complete response rates for FDA-approved therapies pembrolizumab and valrubicin are of 41% and 18%, respectively1 & 2 In addition, for patients with papillary disease, a disease-free survival rate at 18 months of 53%, which more than doubles the 25% rate published by the International Bladder Cancer Group as clinically meaningful A cystectomy avoidance rate of over 90% (91% of CIS patients and 95% of papillary patients) A 96% avoidance rate of progression to muscle invasive bladder cancer for CIS patients who responded to therapy Zero treatment-related or immune-related adverse events or grade 4/5 adverse events https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-over-24-months-median-duration-complete?field_nir_news_date_value[min]=

PSS hat erklärt warum er doch keine neuen Aktien im Dezember ausgegeben hat und stattdessen IBRX duch Fremdkapital (bzw. sein eigenes Kapital) finanzierte: https://www.investmentweek.co.uk/news/4044736/biotech-sell-continues-investors-turn-safer-assets-amid-rising-inflation-reports (ganz am Ende des Artikels)

JP Morgan Asset Management doubled stake in IBRX: https://money.cnn.com/quote/shareholders/shareholders.html?symb=IBRX&subView=institutional

ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-promising-clinical-study-results-kick-and?field_nir_news_date_value[min]=

ImmunityBio’s Acquisition of State-of-the-Art Manufacturing Plant in New York https://www.globallegalchronicle.com/immunitybios-acquisition-of-state-of-the-art-manufacturing-plant-in-new-york/

ImmunityBio founder discusses goals for Athenex plant https://www.observertoday.com/news/page-one/2022/01/immunitybio-ceo-discusses-goals-for-athenex-plant/

Es gibt einen patentfreien Impfstoff, der in Indien bereits zugelassen ist. Es basiert auf einer Gruppe von Wissenschaftlern, die unter Anderem mit ImmunityBio zusammenarbeiten. Hier ein Interview dazu auf spanisch: https://www.eldiarioar.com/sociedad/coronavirus/cientifica-detras-corbevax-vacuna-texas-patentes-esperanza-cambiar-paradigma_128_8694478.html ImmunityBio wird darin erwähnt, allerdings Immunity Bio geschrieben.